Agomab Raises $200M in IPO to Tackle Chronic Fibrotic Diseases

ANTWERP, Belgium – February 09, 2026 – Agomab Therapeutics NV, a clinical-stage biopharmaceutical company, has successfully closed its initial public offering on the Nasdaq, raising approximately $200 million in gross proceeds. The Belgian firm, which is developing therapies for inflammatory and fibrotic diseases, announced today the closing of its offering of 12,500,000 American Depositary Shares (ADSs) at a price of $16.00 per share.

The company’s shares began trading on the Nasdaq Global Select Market on Friday, February 6, under the ticker symbol “AGMB.” The significant capital injection marks a major milestone for Agomab, providing substantial funding to advance its pipeline of novel therapies aimed at conditions with high unmet medical needs.

Navigating a Selective Market

The IPO, managed by a syndicate of top-tier investment banks including J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen, represents a significant vote of confidence from investors. However, the company's debut reflects the cautious nature of the current biotech market. AGMB shares opened for trading at $14.70 and closed their first day at $14.65, approximately 8% below the IPO price.

This performance comes amid a complex environment for biotech IPOs. After a sluggish 2025, which saw the fewest public offerings in the post-pandemic era, the market in early 2026 has shown signs of a rebound, albeit a highly selective one. Investors are no longer rewarding every new listing with a first-day pop, instead focusing on companies with strong clinical data, clear paths to commercialization, and experienced leadership. Agomab’s ability to secure a $200 million purse in this discerning climate underscores the perceived strength of its scientific platform and therapeutic candidates, even if public market enthusiasm was initially tempered.

The offering also includes a 30-day option for underwriters to purchase up to an additional 1,875,000 ADSs, which could add to the total proceeds if exercised.

Fueling a Pipeline for Unmet Needs

Agomab has earmarked the substantial proceeds to propel its clinical-stage programs forward, with a primary focus on its two lead candidates targeting debilitating fibrotic diseases.

A significant portion of the funds will be used to advance ontunisertib (AGMB-129), an oral, gastrointestinal-restricted inhibitor of the ALK5 enzyme. This drug is being developed for Fibrostenosing Crohn's Disease (FSCD), a severe complication of Crohn's that causes intestinal narrowing and obstruction. Currently, there are no approved therapies specifically for FSCD, leaving patients to face invasive surgeries. Ontunisertib recently delivered positive topline results from a Phase 2a trial, meeting its primary safety endpoints and confirming its targeted action with low systemic exposure. Buoyed by this data and a Fast Track Designation from the U.S. FDA, Agomab plans to launch a global Phase 2b study in the second half of 2026.

The second key program is AGMB-447, an inhaled ALK5 inhibitor designed to treat Idiopathic Pulmonary Fibrosis (IPF), a progressive and fatal lung disease. By delivering the drug directly to the lungs, Agomab aims to maximize efficacy while minimizing the systemic side effects that have hindered other drugs targeting the same biological pathway. AGMB-447, which has received Orphan Drug Designation from the FDA, is also expected to enter Phase 2 development later this year following promising Phase 1 data.

Beyond its lead assets, the company will also fund the development of its preclinical candidates, including AGMB-101, a regenerative antibody with potential applications in liver cirrhosis.

A Targeted Approach to Fibrosis

At the core of Agomab's strategy is a sophisticated approach to tackling fibrosis, the harmful scarring of organs that drives diseases like FSCD and IPF. The company targets well-established biological pathways, primarily the Transforming Growth Factor beta (TGFβ) pathway, a master regulator of fibrosis. While TGFβ has long been a target of interest, developing safe and effective drugs has proven challenging due to its widespread roles in the body.

Agomab’s innovation lies in its modality. By developing localized inhibitors—one restricted to the gut and another delivered via inhalation—the company believes it can block the fibrotic signaling where it matters most, avoiding the toxicities associated with systemic inhibition. This refined approach, which aims to overcome the limitations of prior therapeutic strategies, has been validated by backing from prominent life sciences investors like Fidelity, EQT Life Sciences, Pfizer Ventures, and Sanofi even before its public debut.

From Europe to the Global Stage

The successful Nasdaq listing marks a pivotal moment in Agomab’s transition from a promising European biotech to a publicly-traded company with global ambitions. Led by CEO Tim Knotnerus and an experienced management team, the company has navigated the complex journey to the U.S. public markets to access the deep pool of capital required for late-stage clinical development.

This move not only provides the financial firepower to run large, definitive clinical trials but also raises the company's profile on the world stage. As Agomab pushes its potentially disease-modifying therapies through the clinic, the capital and visibility gained from its IPO will be critical in its quest to bring new hope to patients suffering from the devastating effects of chronic fibrotic diseases.